Future horizons for calcitonin: a U.S. perspective

Area of Science:

• Endocrinology
• Pharmacology
• Bone Metabolism

Background:

• Injectable salmon calcitonin (SC) is an established treatment for postmenopausal osteoporosis, Paget's disease, and hypercalcemia.
• Current injectable formulations present challenges including systemic side effects, inconvenience, and patient noncompliance.
• Development of alternative delivery methods for SC is crucial for improving patient adherence and therapeutic outcomes.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a novel nasal salmon calcitonin formulation.
• To compare the nasal formulation's effectiveness against the injectable form in preventing bone loss and restoring bone mass.
• To assess the nasal formulation's potential in reducing pain associated with bone diseases.

Main Methods:

• Clinical trials are underway to compare the nasal SC formulation with the injectable SC.
• Studies focus on bone loss prevention, bone restoration, and pain reduction efficacy.
• Tolerability assessments include monitoring for systemic side effects and nasal irritation.

Main Results:

• The nasal formulation of salmon calcitonin has demonstrated good tolerability in initial studies.
• No significant nasal irritation was noted in subjects receiving the nasal spray.
• The nasal formulation appears to be a promising alternative to injectable SC.

Conclusions:

• Nasal salmon calcitonin offers a potentially well-accepted alternative to injectable formulations, particularly for asymptomatic patients.
• The nasal route may improve compliance by reducing systemic side effects and inconvenience.
• Further research into nasal and oral calcitonin agents is warranted for broader therapeutic applications.